Evidence map›Paper›PMID 41357889›Full record

ReviewFrontiers in pharmacology2025

Research progress on the use of polyphenols in the treatment of Crohn's disease.

Xianmei Zhong, Qian Dai, Jing Li, Jie Yang, Xi Zheng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xianmei ZhongDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Qian DaiDepartment of Pharmacy, The Fourth Affiliated Hospital of Southwest Medical University, MeiShan, China.
Jing LiSichuan Provincial People's Hospital Medical Group Sichuan Investment Xichang Hospital, Xichang, China.
Jie YangDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xi ZhengDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD), and its specific etiology is still unclear. However, it is currently widely believed that this disease is the result of interactions among four main factors: host genetic factors, environmental factors, dysbiosis of the gut microbiota, and an abnormal immune system response. In recent years, polyphenolic compounds have become a research hotspot due to their anti-inflammatory, antioxidant, and microbial regulatory properties, demonstrating potential application value in the treatment of CD. This review aimed to explore the mechanism of action of polyphenolic compounds in the treatment of CD, as well as their progress in animal model research and clinical practice.

Indexed as

anti-inflammatoryantioxidantcrohn’s diseaseinflammatory bowel diseasepolyphenols

Identifiers

PMID41357889
PMCPMC12676250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.